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Many  developing  countries  lack  or  have  inadequate  pandemic  inﬂuenza  vaccine  manufacturing  capac-
ity.  In the  2009  H1N1  pandemic,  this  led  to delayed  and  inadequate  vaccine  coverage  in  the  developing
world.  Thus,  bolstering  developing  country  inﬂuenza  vaccine  manufacturing  capacity  is  urgently  needed.
The Cantacuzino  Institute  in  Bucharest,  Romania  has  been  producing  seasonal  inﬂuenza vaccine  since  the
1970s,  and  has  the capacity  to produce  ∼5 million  doses  of  monovalent  vaccine  in  the  event  of  an  inﬂuenza
pandemic.  Inclusion  of  an  adjuvant  in  the  vaccine  could  enable  antigen  dose  sparing,  expanding  vaccine
coverage  and  potentially  allowing  universal  vaccination  of the  Romanian  population  and  possibly  neigh-andemic inﬂuenza
accine adjuvant
il-in-water emulsion
boring  countries.  However,  adjuvant  formulation  and  manufacturing  know-how  are  difﬁcult  to  access.
This manuscript  describes  the  successful  transfer  of oil-in-water  emulsion  adjuvant  manufacturing  and
quality  control  technologies  from  the  Infectious  Disease  Research  Institute  in  Seattle,  USA to  the  Can-
tacuzino Institute.  By  describing  the  challenges  and  accomplishments  of the  project,  it is  hoped  that  the
knowledge  and  experience  gained  will  beneﬁt  other  institutes  involved  in  similar  technology  transfer
projects  designed  to  facilitate  increased  vaccine  manufacturing  capacity  in developing  countries.. Introduction
The Infectious Disease Research Institute (IDRI) in Seattle, USA
s a non-proﬁt biotechnology institute dedicated to developing
accines, diagnostics, and drugs for diseases that affect develop-
ng countries. IDRI has employed stable oil-in-water emulsions as
djuvants in inﬂuenza vaccines to facilitate antigen dose sparing,
nhanced immunogenicity, and broadened pathogen protection
1–3]. Since access to adjuvants and formulation expertise is dif-
cult to obtain, IDRI’s main objectives include transferring the
anufacturing and quality control (QC) know-how of adjuvant pro-
uction to developing countries.
The National Institute for Research and Development in
icrobiology and Immunology “Cantacuzino” (designated as CI
ereafter) was founded in 1921 by Professor Ion Cantacuzino,
nder the original name of Institute for Serums and Vaccines “Dr.
. Cantacuzino”. Built as an integrated structure, the Institute con-
ucts research in areas of microbiology, immunology and related
ciences, produces vaccines, performs public health activities
technical and methodological support for microbiology laborato-
ies in Romania) and trains medical and scientiﬁc personnel. CI has
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produced seasonal inﬂuenza vaccine for over 40 years, including
an H1N1 vaccine during the 2009 pandemic.
CI currently has the capacity to produce ∼5 million doses of
monovalent pandemic inﬂuenza vaccine antigen (sufﬁcient for
vaccinating 2.5 million people assuming 2 doses of vaccine are
needed). With a population of ∼21 million, Romania would there-
fore need to look for an external supplemental source of vaccine
in the event of a pandemic in order to provide universal cov-
erage. However, inclusion of a vaccine adjuvant could facilitate
several-fold dose sparing, potentially enabling vaccine coverage
for the Romanian population. For example, compared to the non-
adjuvanted split inactivated H5N1 vaccine dose licensed in the
US, the literature indicates that squalene-based oil-in-water emul-
sions may  provide ∼24 fold dose sparing capacity [4,5]. Increasing
the ability of any country to make inﬂuenza vaccines helps every
country reduce the spread of inﬂuenza since in a pandemic every-
one in the world would need a vaccine to be protected. Today,
the capability to make vaccine in every country does not exist.
In 2010 the US Biomedical Advanced Research and Develop-
ment Authority (BARDA) awarded a cooperative agreement to
IDRI to transfer adjuvant manufacturing technology to CI to facili-
Open access under CC BY-NC-ND license.tate pandemic inﬂuenza preparedness. The cooperative agreement
consisted of two  phases, with funding for the second phase (pre-
clinical evaluation of adjuvanted vaccine, US$640,234) contingent
upon the success of the ﬁrst phase (technology transfer of adjuvant
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Table 1
SE release test methods and speciﬁcations (4%, v/v oil).
Test Speciﬁcation
Appearance (visual) Milky-white liquid
Squalene quantitation (GC) 27.5–41.2 mg/ml
Osmolality (vapor pressure) 250–350 mmol/kg
pH  5.0–6.5
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iParticle size (dynamic light scattering) 120 ± 40 nm
anufacturing technology, $US790,200). IDRI was selected as a
artner based on its extensive development and clinical experience
ith adjuvant formulations. CI was selected based on its history
f inﬂuenza vaccine production and because it is one of fourteen
HO-supported developing country inﬂuenza vaccine manufac-
uring partners. This manuscript describes the accomplishment
f the goals for phase I of the cooperative agreement: the suc-
essful technology transfer of vaccine adjuvant manufacturing and
uality control from IDRI to CI. In order for the technology trans-
er project to be successful, it was determined a priori that three
atches of adjuvant, independently manufactured by CI within 10
onths of the initiation of the cooperative agreement, would need
o pass the QC speciﬁcations listed in Table 1 and described below.
n addition, the following criteria were established regarding
djuvant–antigen mixtures for each of the three adjuvant batches
s measured up to 24 h after mixing: equivalent single radial
mmunodiffusion (SRID) hemagglutinin (HA) concentration com-
ared to antigen without adjuvant, <40 nm change in particle size
ompared to adjuvant without antigen, and <1 unit change in pH
ompared to antigen without adjuvant, with all mixtures stored at
–8 ◦C.
. Adjuvant technology
Oil-in-water (o/w) emulsions developed at IDRI consist of
etabolizable oils emulsiﬁed with biocompatible emulsiﬁers in
n aqueous bulk phase [6–10]. Emulsion droplets are ∼100 nm in
iameter and batches manufactured at IDRI with research-grade
aterials show long-term stability at 5 ◦C (Fig. 1). The IDRI sta-
le emulsion (SE) is similar to a formulation already approved
n Europe for inﬂuenza vaccines, MF59®, although the squalene
ose in SE is 2% (v/v) compared to the 2.3% (v/v) in MF59®. It
s important to note that no association between narcolepsy and
F59®-containing vaccines has been found [11] and MF59® has
een shown to have an excellent safety record with millions of
oses administered to all age groups [12]. In contrast, clinical
esearch conducted by the Finnish National Institute of Health and
elfare has led them to hypothesize that rare cases of narcolepsy
n young people in Finland may  be associated with a pandemic
nﬂuenza vaccine containing the emulsion adjuvant AS03 [13].
S03 differs from SE and MF59® in that it contains 2.5% (v/v)
qualene as well as 2.5% (v/v) of an additional oil, -tocopherol.
n addition, the primary emulsiﬁer in SE is phospholipid, whereas
S03 and MF59® contain non-ionic surfactant. Oil-in-water emul-
ions have been shown to effectively and safely induce immune
esponses to inﬂuenza antigens, including enabling antigen sparing
nd cross-clade neutralizing antibody responses [1,14–17]. Exten-
ive preclinical animal testing in various animal models has not
evealed any safety concerns with the SE formulation transferred
o CI [18] or SE variations [2].  Likewise, clinical testing of SE-based
ormulations such as GLA-SE or MPL-SE has revealed no safety
ssues [19,20].  Since the purpose of the project was  to transfer a
oyalty-free adjuvant technology, it is important to note that the
omposition of SE described herein is free of intellectual property
nfringements. (2013) 1633– 1640
The SE manufacturing procedure for a ﬁnal batch size of
550–600 ml  is diagrammed in Fig. 2. The SE is prepared by ﬁrst
mixing squalene oil (27.4 g) and egg phosphatidylcholine (6.1 g)
in a 1-l glass media bottle by water bath sonication at 70 ◦C for
1–2 h until the phosphatidylcholine is dissolved. Next, 1.5 l of
aqueous phase is prepared by dissolving poloxamer 188 (0.037%,
w/v) and glycerol (2.37%, w/v) into ammonium phosphate buffer
(24.3 mM  ammonium phosphate monobasic and 1.3 mM ammo-
nium phosphate dibasic) with ﬁnal aqueous phase pH of 5.6 ± 0.2.
Then, 768 ml  of aqueous phase is added to the oil phase pre-
pared earlier as described above. The crude emulsion is then high
speed mixed (L5M-A Laboratory Mixer, Silverson Machines Ltd.,
with ¾ in. tubular mixing assembly and square hole high shear
screen mixing head) at ∼10,000 rpm for a minimum of 10 min
and then transferred to a high pressure homogenizer (M-110EH-
30 Pilot/Production Processor, Microﬂuidics Corp.), operating at
30,000 psi and water-cooled by a recirculating chiller set to 10 ◦C.
The emulsion is recirculated in the homogenizer for approximately
16 cycles based on the measured ﬂow rate of the M110EH and
the emulsion volume (i.e. 800 ml). Prior to and immediately after
processing, the microﬂuidizer is cleaned by processing 1.5 l of Con-
trad 70 (Decon Labs Inc.) and 0.5 M NaOH, with water-for-injection
ﬂushing of the cleaning agents before and after processing. In a lam-
inar ﬂow hood, the ﬁnal formulation is ﬁlter-sterilized through a
0.2 m ﬁlter (Millipore Millipak-40) under constant ﬂow via peri-
staltic pump. Final emulsion yield is generally 550–600 ml  after
dead volume losses in the homogenization and ﬁltration processes.
QC of the adjuvant is ensured through assessment of physi-
cal appearance, particle size, squalene content, pH and osmolality
(Fig. 1 and Table 1). Visual appearance is performed manually under
adequate lighting by gently swirling a sample of the emulsion
in a glass vial and assessing whether the appearance is milky-
white and homogeneous. Particle size is measured by dynamic
light scattering (Zetasizer Nano-S, Malvern Instruments Ltd.) fol-
lowing system suitability assessment using dispersions of 60 nm
and 220 nm polystyrene beads. Triplicate emulsion samples are
prepared for particle size measurement by diluting them 100-
fold into sterile water for injection in a disposable polystyrene
cuvette. Particle size is reported as Z-avg, which is the average
droplet size of the intensity-based distribution proﬁle. Squalene
content is quantiﬁed by ﬂame ionization gas chromatography
(7890A GC System, Agilent Inc.) by ﬁrst preparing squalene stan-
dards in 2:1 (v:v) chloroform:methanol in volumetric ﬂasks and
preparing triplicate emulsion samples by diluting them 80-fold into
2:1 chloroform:methanol. System suitability is monitored by eval-
uating six injections of a squalene standard for retention time (≤5%
CV), peak area (≤5% CV), tailing factor (between 0.7 and 2), and
capacity factor (k′ ≥ 2.5). The standard curve must have a correla-
tion coefﬁcient of ≥0.995 and an in-process standard injected at
the end of each sample set must be ≤5% different from the actual
concentration. Squalene concentration of the emulsion sample is
then calculated from the squalene standard curve. Measurement of
pH on a sample of emulsion is conducted by a standard electrode
device calibrated previous to measurement. Osmolality is assessed
by vapor pressure osmometry (Vapro Vapor Pressure 5520 or 5600,
Wescor Inc.) with the instrument calibrated with vendor-supplied
standards prior to measurement of triplicate samples, which are
pipetted to the sample holder as undiluted 10-l aliquots. Emul-
sion stability over time is monitored by periodic assessments of
visual appearance, particle size, and pH. In addition, emulsions
manufactured under cGMP conditions undergo further release test-
ing for bioburden, sterility, safety and pyrogenicity. However, the
goal of this technology transfer project was the manufacture of
three engineering batches meeting the speciﬁcations in Table 1,
which did not necessitate cGMP conditions or further release
testing.
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Fig. 1. Physicochemical characterization of SE. (a) Particle size as measured by dynamic light scattering of SE adjuvant stored at 5 ◦C (manufactured at IDRI and employing
research-grade squalene). Average particle size values of a single batch of SE are shown. Error bars representing standard deviation of nine total measurements on three
separate  aliquots at each timepoint are plotted but not visible due to very low magnitude. (b) SE particle size distribution by intensity as measured by dynamic light scattering.
Nine  total measurements were made on three separate aliquots from the same batch of SE. (c) Gas chromatography-ﬂame ionization detection of squalene content in SE
adjuvant.
Fig. 2. Process ﬂow diagram of SE manufacturing procedure.
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. Inﬂuenza antigen
The Cantacuzino Institute (CI) in Bucharest, Romania has pro-
uced seasonal inﬂuenza vaccine since 1971. Recently, CI has
eveloped whole and split pandemic virus antigens, including
n inactivated split virus H5N1 antigen (NIBRG-14 reassor-
ant) that has been evaluated preclinically. Batches of H5N1
A/Vietnam/1194/2004 – NIBRG-14) split virion have been pro-
uced in CI’s vaccine facility following the same technological
ow used for production of seasonal inﬂuenza vaccines. Inﬂuenza
accines are manufactured at CI according to the seasonal WHO
ecommendation for the Northern Hemisphere. Speciﬁc vaccine
roduction details and quality control speciﬁcations are described
n the Supplementary Information. After the quality is checked by
he Quality Control Laboratory of CI, the vaccine receives approval
or marketing release from the National Agency for Medicines and
edical Devices. The main goal of this adjuvant technology trans-
er project was to enable the combination of SE adjuvant developed
y IDRI with the inactivated split virus H5N1 antigen developed
y CI and by so doing to signiﬁcantly reduce the antigen dose
nd/or number of immunizations required to elicit a seroprotective
esponse to the antigen.
. Technology transfer process
.1. Communication
A communication strategy was established at the kick-off tele-
onference which included establishing biweekly teleconferences
nd three face-to-face meetings between CI, IDRI, and BARDA. Prior
o each meeting, an agenda was sent out with highlights and action
tems from the previous meeting. In addition to meetings, emails
ere constantly exchanged and quarterly grant progress reports
ere prepared and submitted.
.2. Equipment and supplies acquisition
Dedicated process and QC equipment was purchased directly
y the Cantacuzino Institute from various suppliers. Production
quipment was mentioned above and included a high pressure
omogenizer, also called a microﬂuidizer (Microﬂuidics M-110EH-
0), a high speed mixer (Silverson L5M-A) and some smaller items,
ll of which were placed in the newly established pilot production
rea for inﬂuenza vaccine development at CI. The QC equipment
ncluded a gas chromatograph (Agilent 7890A), a dynamic light
cattering particle sizer (Malvern Zetasizer Nano-S), and a vapor
ressure osmometer (Wescor Vapro Vapor Pressure 5600). A small
edicated area for QC instrumentation was set up at CI. The equip-
ent purchasing was guided by the national public purchasing
egulations and also the US federal code. Most of the reagents were
urchased by normal purchase channels. Exceptions were particu-
ar GMP  grade reagents such as phosphatidylcholine (Avanti Polar
ipids) and squalene (Sigma-Aldrich Fine Chemicals), where the
urchasing required special attention and involved speciﬁc suppli-
rs and locale.
.3. Translation of SOPs
About 100 pages were provided by IDRI to CI for translation into
omanian. First they were translated faithfully in Romanian, keep-
ng the original IDRI format, to be afterwards adapted to the SOP
ormat used in CI. The initial faithful translations were retained to
nsure the traceability of documents and their modiﬁcations under
his grant. (2013) 1633– 1640
4.4. Visit of CI trainees to IDRI
The initial training of CI scientists was  carried out through a site
visit to IDRI in Seattle, WA,  USA. During the visit, which lasted ﬁve
working days, the CI scientists ﬁrst observed the full manufactur-
ing and characterization process of one batch of adjuvant. Then, the
CI participants manufactured and characterized two  more batches
of adjuvant with guidance from IDRI personnel as necessary. From
CI’s perspective, the visit was informative not only with respect to
the adjuvant manufacturing technology but also for related aspects
such as the type of analytical laboratory required for this type
of product, since traditional biological process laboratories differ
slightly in technology.
4.5. IDRI visits to CI
While awaiting the completion of the equipment acquisition
process, IDRI personnel visited CI in Bucharest, Romania for two
days. This face-to-face meeting facilitated consideration of appro-
priate equipment installation locations and contingency planning.
A more extensive, ﬁve-day visit of an IDRI team to CI occurred after
critical equipment and supplies were installed. Two  pilot lots of
adjuvant were manufactured and characterized under IDRI super-
vision using the newly installed equipment at CI. These pilot lots
were distinct from the three additional lots independently pro-
duced by CI following the site visit. Critical product speciﬁcation
testing was  successfully conducted by the CI staff. The two pilot
adjuvant lots were also included in SRID assays at CI during the
week of the visit and test results indicated that no detrimental
effects on HA content were caused by mixing the antigen with the
adjuvant.
Besides the manufacture of the two pilot lots of adjuvant, an
extensive preclinical study planning session was held, including
a tour of the animal facilities at CI where most of the preclin-
ical studies will be conducted in the second phase of the project.
Subsequent to the 2nd site visit to CI, a consultation with the Euro-
pean Medicines Agency was carried out to discuss the development
and planned use of the adjuvant technology in Romania, and to
receive useful guidance regarding the preclinical development of
the adjuvanted vaccine. In addition, CI is undertaking efforts to be
established as a pre-qualiﬁed WHO  inﬂuenza vaccine manufactur-
ing site.
Finally, on the last day of the visit, all interested CI personnel
as well as local university students and faculty were invited to
attend a one-day adjuvant training course provided by the IDRI
team. Covered were adjuvant history and a current overview of the
ﬁeld, adjuvant mechanisms of action, TLR agonist design and activ-
ity, formulation and characterization, emulsion manufacturing and
QC, adjuvant in vivo activity assays, antigen process development,
and future prospects in adjuvant science.
From the perspective of CI, this training visit was  a good oppor-
tunity for an evaluation of the facilities and for performance
veriﬁcation. The manufacturing of the two  pilot batches increased
the degree of conﬁdence for the CI team and allowed CI to expand
the number of persons trained, thus providing better sustainability
of the manufacturing process. The adjuvant lectures enabled CI sci-
entists to extend their knowledge regarding the new generation of
adjuvants, and were a perfect means to obtain an overview of the
ﬁeld.
5. Results5.1. Independent production of three adjuvant batches at CI
This project required evidence that, within 10 months of
the cooperative agreement award notiﬁcation, CI produce and
C.B. Fox et al. / Vaccine 31 (2013) 1633– 1640 1637
Table  2
Emulsion manufacturing process performance.
Batch Volume (ml, post-high
speed mixing)
Volume (ml, post-
microﬂuidization)
Yield (%) Volume (ml,
pre-ﬁltration)
Volume (ml,
post-ﬁltration)
Yield (%)
1 797 672 84 643 591 92
2 799  670 84 645 588 90
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uccessfully test three engineering lots of oil-in-water stable emul-
ion adjuvant (SE). Accordingly, three lots of SE were manufactured
t CI according to the method described above. Process parameters
ere reproducible as shown in Table 2. The expected small losses
n product yields were largely due to homogenizer and ﬁltration
evice dead volume.
QC testing of the product was performed post-sterile ﬁltration
t CI according to the deﬁned SOPs of the methods in Table 1. All
hree batches of SE produced at CI met  each required speciﬁca-
ion (Table 3). Aliquots from each batch were shipped to IDRI for
onﬁrmation of QC results. The high reproducibility of the charac-
erization results between the two labs is striking (Table 3).
.2. Antigen–adjuvant compatibility
Besides adjuvant QC, an important consideration for the ﬁnal
accine product is to ﬁnd modalities to assess the compatibility
nd stability of the antigen–adjuvant mixture. Unfavorable inter-
ctions could impair the stability of the hemagglutinin structure
tself, which changes conformation at slightly acidic pH. There-
ore, it is important that the virus preparation be kept at a pH
reater than 6.5. Since the pH of the adjuvant is approximately
.6, a good buffering system is needed to maintain the HA confor-
ation. Therefore the buffer of the vaccine diluent was designed
ith a high buffering capacity in the neutral range (7.2). As seen
n Table 4, no major drop in pH occurred after mixing the anti-
en with adjuvant. The pH was checked up to 24 h after mixing
ith little change. In addition, visual appearance and osmolal-
ty were evaluated on selected samples and, as expected, showed
ittle change since antigen and adjuvant had similar osmolality
alues before mixing (data not shown). Moreover, the stability of
he antigen–adjuvant mixture was assessed by monitoring changes
n particle size and HA content. If antigen conformational change
ccurs, the virus exposes hydrophobic regions, leading to aggre-
ate formation and antigen degradation. As can be seen in Table 4,
o signiﬁcant differences in particle size or SRID results are appar-
nt.
To quantify the expected lower doses of antigen, earlier work at
I validated a modiﬁed SRID assay (to account for adjuvant inclu-
ion) for a larger range of antigen concentrations. The differences
oticed are below the statistical signiﬁcance of the test and there-
ore we can assume the antigen compatibility is good for the three
atches. The intra-assay coefﬁcient of variation (CV) obtained dur-
ng the method validation for the HA concentration of 30 g/ml
as, on average, 3.3% with a maximum value of 4.3%. For the com-
atibility assay the CV ranged between 4.7 and 6.1%. Also, regarding
he apparent particle size, the values were stable during 24 h incu-
ation at 2–8 ◦C. Therefore, all three lots met  QC speciﬁcations and
re compatible with a test antigen preparation. The presence of the
il-in-water adjuvant did not inﬂuence the antigen concentration
etermined by SRID at a ∼15 g/0.5 ml  dose during 24 h at 2–8 ◦C.
Since the three batches of adjuvant were manufactured within0 months from the initiation of the cooperative agreement and
assed all established speciﬁcations for quality control and anti-
en compatibility, the technology transfer process was considered
uccessful. Another outcome of the efforts in phase I of the project626 556 89
was a preclinical plan for the in vivo evaluation of the adjuvanted
vaccine. The plan was  designed to demonstrate the immunogenic-
ity, protective efﬁcacy, dose sparing capacity, and safety of the
adjuvanted vaccine in small animal models following applicable
EMA  regulatory guidelines. This plan will be implemented during
phase II of the project (2011–2012). Longer-term plans for fur-
ther development, such as a Phase I clinical trial, and sustainability
are under discussion. This includes development of appropriate
ﬁll/ﬁnish procedures, with initial stability evaluations indicating
that inert gas overlay may  be required. The initial vaccine pre-
sentation is designed as a two-vial system with bedside mixing
of adjuvant and antigen, as with current pandemic vaccine conﬁg-
urations involving AS03 [21]. However, ease of use considerations
may  favor a single vial system or a pre-ﬁlled syringe. For this rea-
son, ongoing studies are evaluating long term stability of single vial
preparations, including methods of improving stability.
6. Lessons learned
6.1. Facility considerations and regional availability of
equipment/supplies
Romania is ideally located within the European Union so it
would be amenable to technology transfer. Unlike most Euro-
pean countries, Romania is a developing country still requiring
technological and economic assistance for development, but is
required to strictly obey the EU laws and regulations including
for manufacturing, research, environmental, and taxation; thus,
medicinal products produced in Romania such as vaccines are
regulated by the European Medicines Agency (new products) as
well as the local national authority (already registered products).
Other regulations can also have an impact on the technology trans-
fer. For example, the microﬂuidizer cleaning detergent Contrad
70 had to be replaced with a different biodegradable version in
the Romanian market as required by EU environmental regula-
tions. The EU market provided access to a diversity of equipment
and supplies not readily available in the Romanian regional mar-
ket, or at greater costs. Available equipment and supplies were
purchased directly by CI from regional suppliers, which avoided
potential delays from customs and import regulations require-
ments.
6.2. Flexibility for time delays
Some delays were experienced due to the public tender process
and the regional unavailability of basic lab supplies. The accelerated
timeline of the project required forward thinking to arrange for
suitable alternatives in such cases. Overall the lesson learned is that
timing of such complex projects should be carefully estimated, with
extra time included for unexpected delays.
6.3. Ambient effectsOne unexpected issue was the inﬂuence of the humidity in
the manufacturing area. Although relative humidity is not usually
deﬁned as a critical parameter in the bioprocess pilot area, this
1638
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Table 3
Emulsion quality control.
Batch Cl visual appearance IDRI visual appearance Cl particle size
(Z-avg, nm)
IDRI particle size
(Z-avg, nm)
Cl squalene
(mg/ml)
IDRI squalene
(mg/ml)
Cl osmolality
(mmol/kg)
IDRI osmolality
(mmol/kg)
CI pH IDRI pH Cl
pass/fail
IDRI
pass/fail
1 Milky-white liquid Milky-white liquid 101.1 101.1 34.3 33.6 310 306 5.6 5.7 Pass Pass
2  Milky-white liquid Milky-white liquid 100.6 100.6 35.4 34.1 299 299 5.6 5.7 Pass Pass
3 Milky-white liquid Milky-white liquid 101.2 102.5 35.3 34.9 309 310 5.6 5.7 Pass Pass
Table 4
Adjuvant–antigen compatibility.
Batch Particle size T = 0
(Z-avg, nm)
Particle size T = 8 h
(Z-avg, nm)
Particle size
T = 24 h (Z-avg, nm)
HA content
T = 0 (mg/ml)
HA content
T = 8 h (mg/ml)
HA content T = 24 h
(mg/ml)
pH
antigen
pH antigen-adjuvant
mix
Antigen alone – – – 36.4 35.5 37.7 7.2 –
1 106.2  105.7 105.9 37.9 36.4 40.3 7.2 7.0
2 109.7  105.7 105.4 37.5 34.2 38.5 7.2 7.1
3 107.2  107.4 108.4 33.3 36.6 35.5 7.2 7.0
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articular process was found to be sensitive to the humidity since
hosphatidylcholine will not disperse well into the squalene oil if
t is not mixed immediately after combining. As a pilot produc-
ion facility at CI, some environmental controls were not designed
or extreme environmental conditions (i.e. the cooling system was
ot powerful enough to assure dehumidiﬁcation in the produc-
ion room when outside temperatures were very high as they were
n the Bucharest summer of 2011). As a result the average room
emperature was 24–26 ◦C and the relative humidity was ∼70%,
ompared to estimated conditions in Seattle of room temperature
16 ◦C with a similar relative humidity (∼70%), meaning less air
oisture than in the facility at CI in Romania. Therefore the environ-
ental parameters of the area should be taken into consideration.
.4. Analytical testing
Particle sizing (by dynamic light scattering) can be a challenge
or emulsions. Higher concentrations can produce false size infor-
ation due to interference of multiple light scattering particles.
ur previous experience with a related particle sizing instrument
elped us to avoid these mistakes. In addition, we could compare
he performance of the backscattering-based detection mechanism
n the Zetasizer Nano-S with the 90◦ detection mechanism in a
elated instrument; we found the backscattering detection to be
ore robust, especially at higher particle concentrations. Another
C issue of particular importance was the osmolality determina-
ion. The Pharmacopoeia recommends the freezing point method
nd this was adopted by CI, whereas the technology transfer called
or the vapor pressure method; thus, CI performed both meth-
ds. Glycerol and macromolecules behave anomalously with the
reezing point method, and therefore the results were dramatically
ffected. In summary, QC methods and equipment speciﬁcations
ust be followed exactly for successful performance.
. Conclusions and recommendations
This project was successfully executed with a cross-cultural
eam. Working in two countries in two different types of institutes
ecessitates understanding the laws and regulations of each. IDRI
nd CI have developed a working model for the transfer of sta-
le emulsion adjuvant technology from one institution to another.
lthough this project was speciﬁcally intended to provide dose
paring for a pandemic ﬂu vaccine in Romania, the same technology
ould be useful in other countries or in dose-sparing other vaccines
here there is a critical need and the vaccine is in short supply.
he cost of this program is relatively modest (e.g. $790,200 for the
djuvant technology transfer phase) for the tremendous potential
eturn on investment expected through antigen dose-sparing and
andemic inﬂuenza preparedness. Of course, long-term follow-up
nd development will be necessary to ensure consistent results,
ncluding manufacturing scale-up and development of additional
xcipient characterization assays (e.g. emulsiﬁer quantitation) in
rder to ensure adequate adjuvant supply and comprehensive
uality control. These efforts are ongoing. We  propose that other
echnology transfer efforts can beneﬁt from the lessons learned
uring the present project.
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